# Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

> **NCT00275431** · PHASE2 · COMPLETED · sponsor: **Ascenta Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- Follicular Lymphoma
- Diffuse Large Cell Lymphoma
- Mantle Cell Lymphoma
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** AT-101

## Key facts

- **NCT ID:** NCT00275431
- **Lead sponsor:** Ascenta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275431, "Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00275431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*